Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.58 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.57 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.57 |
| ▸ | NMT1 | P30419 | 1/20 | 0.49 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.48 |
| ▸ | ACHE | P22303 | 2/20 | 0.46 |
| ▸ | TLR7 | Q9NYK1 | 2/20 | 0.45 |
| ▸ | SIGMAR1 | Q99720 | 6/20 | 0.44 |
| ▸ | TRPC5 | Q9UL62 | 1/20 | 0.44 |
| ▸ | MAP3K11 | Q16584 | 1/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2056410 | 0.87 | KDR (0.48) | CYP1A2CYP2D6SIGMAR1TRPC5 | |
| SCHEMBL1108663 | 0.82 | NMT1 (0.54) | HRH3NMT1HRH4ACHETLR7 | |
| SCHEMBL14924463 | 0.81 | NMT1 (0.56) | HRH3NMT1HRH4ACHETLR7 | |
| SCHEMBL21412819 | 0.80 | DPP7 (0.48) | HRH3CYP1A2CYP2D6NMT1HRH4 | |
| SCHEMBL2320244 | 0.79 | NMT1 (0.51) | HRH3NMT1HRH4ACHESIGMAR1 | |
| SCHEMBL4069152 | 0.79 | HRH3 (0.62) | HRH3NMT1HRH4ACHETLR7 | |
| SCHEMBL2998111 | 0.79 | NMT1 (0.48) | HRH3CYP1A2CYP2D6NMT1HRH4 | |
| SCHEMBL13757473 | 0.78 | NMT1 (0.48) | HRH3NMT1HRH4ACHESIGMAR1 | |
| SCHEMBL15247195 | 0.78 | NMT1 (0.48) | HRH3NMT1HRH4ACHETLR7 | |
| SCHEMBL14238180 | 0.78 | ALDH1A1 (0.51) | HRH3NMT1HRH4ACHEMAP3K11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7579348-B2 | Derivatives of 8-substituted xanthines | PGXHEALTH, LLC (US) | 2009-08-25 | — | — | US | disclosed |
| US-20070249598-A1 | Derivatives of 8-substituted xanthines | ADENOSINE THERAPEUTICS, LLC | 2007-10-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070249598-A1 | Derivatives of 8-substituted xanthines | ADORA2B, ADORA2A, ADORA3 | HRH3 354/4885CYP1A2 262/4885CYP2D6 399/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.